Results 151 to 160 of about 3,367,821 (256)

Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders.

Blood, 2005
A. Jones, S. Kreil, K. Zoi, K. Waghorn, Claire Curtis, Lingyan Zhang, J. Score, R. Seear, A. Chase, F. Grand, H. White, Christine Zoi, D. Loukopoulos, E. Terpos, Elisavet-Christine Vervessou, B. Schultheis, M. Emig, T. Ernst, E. Lengfelder, R. Hehlmann, A. Hochhaus, D. Oscier, R. Silver, A. Reiter, N. Cross   +24 more
semanticscholar   +1 more source

Hemostatic disorders in a JAK2V617F-driven mouse model of myeloproliferative neoplasm.

Blood, 2014
Lamia Lamrani, C. Lacout, V. Ollivier, C. Denis, Elizabeth Gardiner, Benoît Ho Ho Tin Noé, W. Vainchenker, J. Villeval, M. Jandrot-Perrus   +8 more
semanticscholar   +1 more source

Analytical cohort study on splenomegaly and cytopenias in myeloproliferative disorders. [PDF]

Bioinformation
Sinha S, Rajan VP, Nair AU, Jakka AP, Chandrasekaran SP.   +4 more
europepmc   +1 more source

Clinical course and short-term outcome of postsplenectomy reactive thrombocytosis in children without myeloproliferative disorders: A single institutional experience from a developing country. [PDF]

PLoS One, 2020
Zvizdic Z, Kovacevic A, Milisic E, Jonuzi A, Vranic S.   +4 more
europepmc   +1 more source

Pediatric Pulmonary Hypertension Associated With Treatment of Myeloproliferative Disorders and Malignant Tumors. [PDF]

Pulm Circ
Chida-Nagai A, Terashita Y, Hirabayashi S, Yamazawa H, Cho Y, Manabe A.   +5 more
europepmc   +1 more source

Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms [PDF]

, 2018
Abboud, Camille N.
core   +1 more source

SFX-01 is therapeutic against myeloproliferative disorders caused by activating mutations in Shp2. [PDF]

EMBO Mol Med
Cho HJ, Smith J, Switzer CH, Louka E, Charles RL, Prysyazhna O, Schroder E, Fernandez-Caggiano M, de Jesus DS, Eminaga S, Yin X, Yang X, Lynham S, Mayr M, Morales V, Bianchi K, Rajeeve V, Cutillas PR, Mead AJ, Eaton P.   +19 more
europepmc   +1 more source

[The role of AKT inhibitors combined with Ruxolitinib in ameliorating myeloproliferative disorders in mice with CALR gene mutations]. [PDF]

Zhonghua Xue Ye Xue Za Zhi
Zhang LW, Zhang QG, Ji MC, Qi KM, Li ZY, Xu KL, Fu CL.   +6 more
europepmc   +1 more source

MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients.

Blood, 2006
A. Pardanani, Ross L. Levine, T. Lasho, Yana Pikman, R. Mesa, M. Wadleigh, D. Steensma, M. Elliott, A. Wolanskyj, W. Hogan, R. Mcclure, M. Litzow, D. Gilliland, A. Tefferi   +13 more
semanticscholar   +1 more source

The Association Between Janus Kinase 2 and Factor V Leiden Mutations and Thrombotic Complications in Patients With Myeloproliferative Disorders: A Study From Saudi Arabia. [PDF]

Cureus
Sayed WS, Al-Bayati A, Elzubair LG, Mohamed S, Alharthi M.   +4 more
europepmc   +1 more source